Conference Coverage

VIDEO: Top hits from 2015 World Diabetes Congress


 

EXPERT ANALYSIS FROM THE WORLD DIABETES CONGRESS

References

VANCOUVER, B.C. – So far, just one of the newer diabetes drugs has been shown to cut cardiovascular risk in type 2 diabetes.

Dr. Bernard Zinman, chairman of the meeting’s program committee, explained which one it is, and also shared other highlights from this year’s World Diabetes Congress.

In an interview at the meeting, Dr. Zinman offered new insights on beta-cell preservation, diabetes prevention, pancreas imaging, the microbiome, and the best combination therapies for early intervention.

“Diabetes is a very complex disease,” said Dr. Zinman, also the director of the diabetes center at Mount Sinai Hospital in Toronto and a professor of medicine at the University of Toronto. “To imagine that there’s one therapy or one magic bullet” that’s going to take care of all the problems in diabetes, “is very naive.”

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

aotto@frontlinemedcom.com

Recommended Reading

Empagliflozin benefited type 2 diabetes patients with CKD
MDedge Cardiology
VIDEO: Study shows how to stand up to the ‘sitting disease’
MDedge Cardiology
AHA: Broadening evidence for CABG over PCI in diabetics
MDedge Cardiology
Blood pressure above 140/80 worsens proteinuric diabetic kidney disease
MDedge Cardiology
AHA: Empagliflozin for T2D reduces heart failure endpoints
MDedge Cardiology
WDC: Alogliptin promotes regression of carotid atherosclerosis in diabetic patients
MDedge Cardiology
Lixisenatide not cardioprotective in type 2 diabetes
MDedge Cardiology
HbA1c strengthens diabetes predictive model more in whites than in African Americans
MDedge Cardiology
Vitamin D improved vascular function in kidney disease
MDedge Cardiology
Experts call for international cooperation on human gene editing
MDedge Cardiology